artificial intelligence, 377
artificial respiration, 568
artificial specific immunity, 340
ARV, 31
ASC09F, 43
assisted ventilation, 568
asthenia, 53
AstraZeneca vaccine, 690
asymptomatic, 44
atibuclimab, 58
attention to grief, 54
ATYR1923, 59
autofiltrante mask, 409
autoinflammation, 60
aviptadil, 63
azithromycin, 64
B cell, 392
B lymphocyte, 392
B-cell, 392
bamlanivimab, 65
baricitinib, 66
basic reproduction number, 721
basic reproductive rate, 721
bat, 544
BBIBP-CorV vaccine, 691
bemcentinib, 68
beneficence, 505
bereavement, 195
bevacizumab, 69
bioethics committee, 128
Ab test, 644
acalabrutinib, 2
ACE inhibitor, 375
acquired immunity, 333
active immunity, 332
acute respiratory distress syndrome, 609
Ad5-nCoV, 692
adaptative immunity, 333
ADG20, 8
adult respiratory distress syndrome, 609
adverse event, 228
aerosol, 10
Ag test, 517
ageism, 201
ageusia, 12
agism, 201
AI, 377
alcohol-based hand gel, 289
alunacedase alfa, 19
ambroxol, 20
AMY-101, 21
anakinra, 22
analgesic, 23
angiotensin-converting enzyme inhibitor, 375
anodyne, 23
anosmia, 24
anti-fog suede, 660
antibiotic, 27
antibody, 28
antibody test, 644
antibody titer, 653
anticipatory anxiety, 25
antigen, 29
antigen test, 517
antigenic load, 95
antipyretic, 30
antiretroviral, 31
clazakizumab, 116
clinic, 117
clinical chart, 318
clinical record, 318
clinical study, 237
clinical trial, 49
clofazimine, 118
close contact, 138
close-distance contact, 138
cluster, 13
co-morbidity, 129
coagulopathy, 120
cobicistat, 123
coexistence bubble, 73
colchicine, 126
Comirnaty, 661
communicable, 665
community immunity, 338
community intervention trial, 51
community spread, 667
community transmission, 667
community trial, 51
comorbidity, 129
compassionate use, 683
complete blood count, 305
conestat alfa, 132
confinement, 133
confirmed case, 99
conjunctivitis, 136
contact, 137
contact follow-up, 541
contact tracer, 542
contact tracing, 541
contact tracking, 541
contagion, 139
contagion curve, 150
contagion rate, 633
contagiosity, 144
contagiousness, 144
containment measure, 425
biological agent, 11
bleeding disorder, 120
blind trial, 46
blinded trial, 46
boceprevir, 70
booster dose, 197
brensocatib, 74
brequinar, 75
brincidofovir, 76
bromhexine, 77
bronchiole, 80
bronchiolitis, 81
bronchiolus, 80
bronchodilator, 78
bronchus, 79
bubble group, 299
budesonide, 84
C-reactive protein, 511
camostat, 87
camrelizumab, 88
canakinumab, 90
CanSino vaccine, 692
capsid, 92
case, 98
case-fatality rate, 634
casirivimab, 104
cassette, 106
CCT, 49
CD24Fc, 107
cenicriviroc, 112
cephalalgia, 109
cephalea, 109
cephalgia, 109
CFR, 634
chest pain, 196
chilblain, 476
chloroquine, 119
CI, 363
ciclesonide, 113
civet, 115
dexamethasone, 180
diagnosis, 182
diagnostic, 182
diarrhea, 183
direct transmission, 140
disability, 185, 359
disability assessment medicine, 420
discarded case, 100
discharge, 18
disinfectant, 176
disinfectant gel, 289
distributive justice, 383
dizziness, 405
DNA, 3
domiciliary care, 55
double-blind test, 47
double-blinded trial, 47
double-masked test, 47
droplet infection, 370
dry cough, 659
dysphonia, 186
dyspnea, 188
dysthanasia, 450
early case finding, 179
early detection, 179
eculizumab, 199
eczema, 200
effective reproduction number, 722
effective reproduction rate, 722
elasomeran, 205
ELISA, 219
emapalumab, 207
emesis, 737
empirical reproduction number, 723
emtricitabine, 212
emvododstat, 213
endemia, 215
enlarged bubble, 72
enoxaparin, 216
enpatoran, 217
containment phase, 265
contention, 145
contingency plan for COVID-19, 492
control, 146
controlled clinical trial, 49
convalescence, 147
Convidecia, 692
CoronaVac, 709
coronavirus disease 2019, 161
coronaviruses, 152
cough, 657
Covid-19, 161
COVID-19, 161
COVID-19 high-risk person, 486
COVID-19 jab, 688
COVID-19 sensitive person, 486
COVID-19 shot, 688
COVID-19 vaccine, 688
COVID-19 Vaccine Janssen, 701
COVID-19 virus, 153
COVID-19 vulnerable person, 486
COVID-2019, 161
culture, 165
cumulative incidence, 363
CureVac vaccine, 694
curfew, 655
CVnCoV, 694
cytokine, 114
cytokine storm, 638
D-dimer, 184
danoprevir, 167
darunavir, 168
dazcapistat, 169
de-escalation, 173
death rate, 635
death with dignity, 431
deconfinement, 172
defenses, 170
dehydrodidemnin B, 494
deoxyribonucleic acid, 3
fomes, 281
fomite, 281
galidesivir, 283
Gam-COVID-Vac, 284
Gamaleya vaccine, 284
general reaction, 551
genome, 291
gimsilumab, 292
glove, 304
goflikicept, 293
grief, 195
gustatory hypoesthesia, 313
hand disinfectant gel, 289
hand hygiene, 310
hand sanitiser gel, 289
hand sanitizer gel, 289
head covering, 105
headache, 109
health authority, 62
health emergency, 210
health file, 318
healthy life expectancy, 232
hemogram, 305
heparin, 306
hepatotoxicity, 307
herd immunity, 338
home care service, 55
home health care, 55
horizontal transmission, 668
hospital care, 56
hospital-acquired infection, 368
host, 320
host species, 320
household bubble, 73
household support bubbles, 72
human pharmacology study, 243
hydroxychloroquine, 308
hygiene, 309
hygienic mask, 411
hypercytokinaemia, 638
ensovibep, 218
envelope, 208
enzyme-linked immunosorbent assay, 219
epi curve, 150
epidemic, 221
epidemic curve, 150
epidemic outbreak, 83
epidemic peak, 490
epidemic wave, 454
epidemiologic curve, 150
epidemiological chain, 86
epidemiological curve, 150
epidemiology, 222
eradication, 225
etesevimab, 249
evaluating medicine, 420
excess deaths, 250
excess mortality, 250
extended bubble, 72
extubation, 256
exudate, 253
face shield, 465
facial screen, 465
false negative, 262
false positive, 263
fatigue, 268
favipiravir, 271
febricula, 273
febrifuge, 30
fenofibrate, 274
ferritin, 275
fever, 272
FFP mask, 409
FFP respirator, 409
fibrinogen, 276
fibrosis, 277
filtering face piece, 409
fingolimod, 278
flatten the curve, 36
Fl√ºgge droplet, 296
inflammation, 373
inflammatory marker, 404
infodemic, 374
inherent immunity, 347
inherited immunity, 347
injection site, 529
injection site reaction, 552
innate immunity, 347
insomnia, 376
intensive care unit, 680
interferon, 378
interferon beta, 379
intermediate host, 321
intubation, 380
isolate, 16
isolation, 14
Janssen COVID-19 vaccine, 701
Janssen vaccine, 701
Johnson & Johnson vaccine, 701
lack of concentration, 264
lactate dehydrogenase, 384
lactic dehydrogenase, 384
lanadelumab, 385
latency, 386
latent period, 478
LDH, 384
lenzilumab, 388
leronlimab, 389
lesser horseshoe bat, 546
life expectancy, 231
life support, 626
life support care, 626
life support limitation, 7
limitation of life support, 7
LLS, 7
local reaction, 552
lockdown, 133
lockdown lifting, 172
long COVID, 163
lopinavir, 398
hypercytokinemia, 638
hypogeusesthesia, 313
hypogeusia, 313
hyposmia, 314
hypoxemia, 316
hypoxia, 317
ibuprofen, 324
icatibant, 325
ICU, 680
idiopathic respiratory distress of newborn, 610
imdevimab, 327
immune, 328, 330
immune response, 570
immunity, 331
immunity certificate, 468
immunity passport, 468
immunization, 349
immunization coverage, 121
immunization schedule, 472
immunochromatographic rapid test, 525
immunochromatography, 351
immunogenic, 352
immunogenicity, 353
immunoglobulin, 354
immunoglobulin G, 355
immunoglobulin M, 356
immunologic, 358
immunological, 358
immunological memory, 421
incidence, 362
incubation, 364
incubation period, 478
incubative stage, 478
index case, 101
indirect transmission, 142
infectiology, 371
infection, 367
infection chain, 86
infectious period, 479
infiltrate, 372
myalgia, 427
nafamostat, 442
nasal cannula, 678
nasal congestion, 135
nasal prongs, 678
nasopharyngeal sample, 434
native immunity, 347
natural specific immunity, 343
nausea, 443
nebulization, 444
nebulizer, 445
neonatal respiratory distress syndrome, 610
net reproductive rate, 722
new epidemic outbreak, 554
new normal, 448
new normality, 448
new wave, 554
nonmaleficence, 506
nonspecific immunity, 347
nosocomial infection, 368
NovaVax vaccine, 449
NVX-CoV2373, 449
occupational health, 580
olfactory hypoesthesia, 314
OP-101, 455
opaganib, 456
oropharyngeal sample, 435
oseltamivir, 458
otilimab, 459
outpatient treatment, 664
Oxford-AstraZeneca vaccine, 690
oxygen therapy, 461
oxygenation, 460
pandemic, 463
pandemic fatigue, 270
pangolin, 464
parasite, 466
passive specific immunity, 344
pathogenic, 470
pathogenicity, 471
LSL, 7
lymphocyte, 391
lymphocytopenia, 396
lymphopenia, 396
macrophage, 399
mask, 406, 407
mask with particulate filter, 409
mass testing, 652
mechanical ventilation, 568
MEDI 3506, 418
medical expertise, 483
medical face shield, 465
medical file, 318
medical mask, 413
medical record, 318
medicalize, 419
memory cell, 393
mental exhaustion, 269
meplazumab, 422
MERS, 613
MERS-CoV, 154
MERS-CoV coronavirus, 154
messenger ribonucleic acid, 577
messenger ribonucleic acid vaccine, 698
messenger RNA, 577
messenger RNA vaccine, 698
methylprednisolone, 426
Middle East respiratory syndrome, 613
mitigation phase, 266
Moderna vaccine, 205
molnupiravir, 428
monitoring, 429
montelukast, 430
mortality, 432
mortality rate, 635
mourning, 195
mRNA, 577
mRNA vaccine, 698
mupadolimab, 438
mutation, 441
prevalence, 503
prevention delegate, 171
prevention service, 601
preventive vaccine, 707
primary health car, 57
primary immunization, 504
primary vaccination, 504
primary vaccine failure, 260
primer, 214
primovaccination, 504
principle of beneficence, 505
principle of nonmaleficence, 506
prioritisation, 508
prioritization, 508
probe, 617
prodrome, 509
prophylactic vaccine, 707
protective leg cover, 500
prothrombin time, 640
public health, 309, 582
public health services, 582
pulmonary embolism, 209
QOL, 531
quality of life, 531
quarantine, 532
quarantine, to, 533
quarantined, 534
radiography, 537
radiomics, 538
randomised clinical trial, 45
rapamycin, 614
rapid test, 525
ravulizumab, 548
RCT, 45
recidivation, 559
recidivism, 559
recrudescence, 560
regdanvimab, 561
reinfection, 563
relapse, 556, 559
patient chart, 318
patient record, 318
PCR, 550
PCR diagnostic test, 521
PCR test, 521
pemziviptadil, 475
peplomer, 233
peplos, 208
perimeter confinement, 134
period of recuperation, 642
permanent disability, 360
personal protective equipment, 223
Pfizer/BioNTech, 661
phagocytosis, 258
phase 0, 242
phase 0 study, 242
phase I, 243
phase I study, 243
phase II, 244
phase II study, 244
phase III, 245
phase III study, 245
phase IV, 246
phase IV study, 246
physical distance, 190
physical distancing, 192
placebo, 493
plitidepsin, 494
pneumonia, 495
polymerase chain reaction, 550
polymerase chain reaction test, 521
pooled sample testing, 519
pooling, 519
pooling samples, 519
post COVID-19 condition, 163
PPE, 223
PPE mask, 409
precautionary principle, 507
preclinical study, 248
prednisolone, 502
sentinel population, 499
sepsis, 592
sequel, 593
serologic test, 526
serological test, 526
serology, 594
seroprevalence, 595
serotherapy, 596
serotype, 597
serovar, 597
serum test, 526
severe, 298
severe acute respiratory syndrome, 612
severe acute respiratory syndrome-related coronavirus, 155
severe acute respiratory syndrome-related coronavirus 2, 153
shelter-in-place order, 133
shock, 739
shock lung, 609
shoe cover, 500
shortness of breath, 188
sign, 602
siltuximab, 603
Sinopharm BIBP COVID-19 vaccine, 691
Sinovac COVID-19 vaccine, 709
Sinovac vaccine, 709
sirolimus, 614
site of injection, 529
site of inoculation, 529
smear, 282
social distance, 190
social distancing, 192
socialization, 616
sotrovimab, 619
species jump, 579
specific immunity, 333
spike, 233
spike glycoprotein, 515
spike protein, 515
remdesivir, 564
remote working, 637
reservoir, 567
respiratory distress syndrome, 609
respiratory distress syndrome of newborn, 610
respiratory droplet, 296
respiratory rehabilitation, 562
retrovirus, 571
revaccination, 573
ribavirin, 574
ribonucleic acid, 4
risk factor, 257
risk group, 303
risk-free certificate, 468
ritonavir, 575
RNA, 4
route of administration, 726
ruxolitinib, 578
S protein, 515
safe distancing, 192
safety distance, 190
sanitarization, 583
sanitizing gel, 289
sarilumab, 584
SARS, 612
SARS virus, 155
SARS-associated coronavirus, 155
SARS-CoV, 155
SARS-CoV-2, 153
SARS-CoV-2 acute respiratory disease, 161
scaly anteater, 464
screening, 164
seasonality, 234
secondary vaccine failure, 261
sedation, 589
self-sample, 61
selinexor, 590
semeiology, 605
semiology, 605
sentinel group, 499
Spikevax, 205
Sputnik V, 284
state of alarm, 236
stay-at-home order, 133
strain, 615
structural protein, 514
subasumstat, 623
superspreader, 624
surgical mask, 413
susceptible, 627
suspected case, 103
suspicious case, 103
swab, 227
symptom, 604
syndemics, 607
systemic reaction, 551
T cell, 394
T lymphocyte, 394
T-cell, 394
tachycardia, 630
target population, 497
telecommuting, 637
telemedicine, 636
teleworking, 637
temporary disability, 361
temporary employment regulation file, 252
tenofovir, 643
thalidomide, 628
therapeutic confirmatory study, 245
therapeutic exploratory study, 244
therapeutic obstinacy, 450
therapeutic overzealousness, 450
therapeutic use study, 246
thoracalgia, 196
thrombosis, 674
thrombus, 673
tixagevimab, 654
tocilizumab, 656
tozinameran, 661
tracheotomy, 670
tracing, 662
transmissible, 665
transmission, 666
transmission chain, 86
treatment withholding, 446
triage, 672
triple-blind test, 48
triple-blinded test, 48
triple-masked test, 48
TRV027, 676
umifenovir, 679
urticaria, 682
vaccination, 712
vaccination coverage, 121
vaccination schedule, 472
vaccine, 687
vaccine adverse reaction, 549
vaccine coverage, 121
vaccine effectiveness, 202
vaccine efficacy, 203
vaccine efficiency, 204
vaccine failure, 259
vafidemstat, 714
variant, 715
variant of concern, 718
variant of interest, 716
vax, 687, 712
Vaxzevria, 690
ventilation, 724
ventilator, 569
VeroCell vaccine, 710
vertical transmission, 669
vidofludimus, 727
viral burden, 96
viral coat, 208
viral load, 96
viral vaccine, 711
viral variant, 715
viricide, 728
virion, 729
virucide, 728
virulence, 730
virus, 731
virus isolate, 16
virus responsible for COVID-19, 153
virus vaccine, 711
virus variant, 715
VOC, 718
VOI, 716
vomiting, 737
vorapaxar, 738
vulnerable group at risk, 125
wave, 454
wet cough, 658
WHO, 457
withholding of treatment, 446
World Health Organization, 457
Wuhan vaccine, 710
zilucoplan, 740
zoonosis, 741
zoonotic, 742
zorecimeran, 694
